Skip to main content
Erschienen in: Clinical and Translational Oncology 1/2014

01.01.2014 | Special Article

Time trends of cancer incidence and mortality in Catalonia during 1993–2007

verfasst von: R. Clèries, L. Esteban, J. Borràs, R. Marcos-Gragera, A. Freitas, M. Carulla, M. Buxó, A. Puigdefàbregas, Á. Izquierdo, R. Gispert, J. Galceran, J. Ribes

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe time trends of cancer in Catalonia, Spain, during the period 1993–2007.

Methods/patients

Data have been provided by two population-based cancer registries, Girona and Tarragona, and the Catalan mortality registry. Cancer incidence in Catalonia has been estimated through modeling methods using data from these health structures.

Results

During 2003–2007, there were 20,042 cancer cases and 9,842 deaths per year among men and 13,673 new cancer cases and 5,882 deaths among women. The most frequent incident cancers among men were prostate (N = 4,258), lung (N = 3,021), colorectal (N = 3,007) and bladder (N = 2,238), whereas among women they were breast (N = 3,907), colorectal (N = 2,088), corpus uteri (N = 734) and lung (N = 527). During 1993–2007, age-standardized incidence rates (ASIRs) rose 1.2 % per year among men [prostate (6.3 %), testis (5.7 %), kidney (2.9 %), liver (2.2 %) and colorectal (2.1 %)]. ASIRs decreased for stomach (−2.9 %), oral cavity and pharynx (−2.8 %), larynx (−2.7 %) and esophagus (−2 %). Among women, ASIRs only rose for lung (5.2 %), kidney (3.1 %), oral cavity and pharynx (2.6 %) and thyroid (1.6 %). ASIRs decreased for corpus uteri (−2.3 %), stomach (−1.7 %) and ovary (−1.6 %). Cancer mortality decreased −1.3 % per year among men and −2.1 % among women during the same period.

Conclusion

Among men, the decrease of incidence/mortality of tobacco-related tumors was related to a reduction of smoking prevalence. Among women, the stabilization of breast cancer incidence and the rise of lung cancer incidence are similar to that observed in most European regions. These results allow assessing the effectiveness of public health strategies and they pose new frontiers for cancer control in Catalonia.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Zurück zum Zitat Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRef Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRef
3.
Zurück zum Zitat Cleries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;10(31):978–87.CrossRef Cleries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;10(31):978–87.CrossRef
4.
Zurück zum Zitat Ribes J, Cleries R, Buxo M, Ameijide A, Valls J, Gispert R. Predictions of cancer incidence and mortality in Catalonia to 2015 by means of Bayesian models]. Med Clin (Barc). 2008;131(Suppl 1):32–41.PubMedCrossRef Ribes J, Cleries R, Buxo M, Ameijide A, Valls J, Gispert R. Predictions of cancer incidence and mortality in Catalonia to 2015 by means of Bayesian models]. Med Clin (Barc). 2008;131(Suppl 1):32–41.PubMedCrossRef
5.
Zurück zum Zitat Sanchez MJ, Payer T, De Angelis R, Larranaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;05(Suppl 3:iii):30–6. Sanchez MJ, Payer T, De Angelis R, Larranaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;05(Suppl 3:iii):30–6.
6.
Zurück zum Zitat Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al, editors. Cancer Incidence in Five Continents, Vol. IX. Lyon: IARC Scientific Publications; 2007. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al, editors. Cancer Incidence in Five Continents, Vol. IX. Lyon: IARC Scientific Publications; 2007.
7.
Zurück zum Zitat World Health Organization. International Classification of Diseases, ninth revision. Geneva: WHO; 1977. World Health Organization. International Classification of Diseases, ninth revision. Geneva: WHO; 1977.
8.
Zurück zum Zitat World Health Organization. International Statistical Classification of Diseases and Related Health problems, tenth revision. Geneva: WHO; 1992. World Health Organization. International Statistical Classification of Diseases and Related Health problems, tenth revision. Geneva: WHO; 1992.
9.
Zurück zum Zitat Esteban L, Cleries R, Galvez J, Pareja L, Escriba JM, Sanz X, et al. REGSTATTOOLS: freeware statistical tools for the analysis of disease population databases used in health and social studies. BMC Public Health. 2013;13(1):201.PubMedCentralPubMedCrossRef Esteban L, Cleries R, Galvez J, Pareja L, Escriba JM, Sanz X, et al. REGSTATTOOLS: freeware statistical tools for the analysis of disease population databases used in health and social studies. BMC Public Health. 2013;13(1):201.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: gLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: gLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
11.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRef
12.
Zurück zum Zitat Malvezzi M, Bertuccio P, Levi F, la Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2013;24(3):792–800.PubMedCrossRef Malvezzi M, Bertuccio P, Levi F, la Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2013;24(3):792–800.PubMedCrossRef
13.
Zurück zum Zitat Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.PubMedCrossRef Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.PubMedCrossRef
14.
Zurück zum Zitat Izquierdo A, Gispert R, Saladie F, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: breast cancer. Med Clin (Barc). 2008;131(Suppl 1):50–2.PubMedCrossRef Izquierdo A, Gispert R, Saladie F, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: breast cancer. Med Clin (Barc). 2008;131(Suppl 1):50–2.PubMedCrossRef
15.
Zurück zum Zitat Pollan M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galceran J, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst. 2009;101(22):1584–91.PubMedCrossRef Pollan M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galceran J, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst. 2009;101(22):1584–91.PubMedCrossRef
16.
Zurück zum Zitat Cleries R, Martinez JM, Moreno V, Yasui Y, Ribes J, Borras JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24(3):454–60.PubMedCrossRef Cleries R, Martinez JM, Moreno V, Yasui Y, Ribes J, Borras JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24(3):454–60.PubMedCrossRef
17.
Zurück zum Zitat Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, la Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21(1):77–82.PubMedCrossRef Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, la Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21(1):77–82.PubMedCrossRef
18.
Zurück zum Zitat Ribes J, Navarro M, Cleries R, Esteban L, Pareja L, Binefa G, et al. Colorectal cancer mortality in Spain: trends and projections for 1985–2019. Eur J Gastroenterol Hepatol. 2009;21(1):92–100.PubMedCrossRef Ribes J, Navarro M, Cleries R, Esteban L, Pareja L, Binefa G, et al. Colorectal cancer mortality in Spain: trends and projections for 1985–2019. Eur J Gastroenterol Hepatol. 2009;21(1):92–100.PubMedCrossRef
19.
Zurück zum Zitat Borras JM, Pareja L, Peris M, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: colorectal cancer. Med Clin (Barc). 2008;131(Suppl 1):58–62.PubMedCrossRef Borras JM, Pareja L, Peris M, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: colorectal cancer. Med Clin (Barc). 2008;131(Suppl 1):58–62.PubMedCrossRef
20.
Zurück zum Zitat Manchon-Walsh P, Borras JM, Espinas JA, Aliste L. Variability in the quality of rectal cancer care in public hospitals in Catalonia (Spain): clinical audit as a basis for action. Eur J Surg Oncol. 2011;37(4):325–33.PubMedCrossRef Manchon-Walsh P, Borras JM, Espinas JA, Aliste L. Variability in the quality of rectal cancer care in public hospitals in Catalonia (Spain): clinical audit as a basis for action. Eur J Surg Oncol. 2011;37(4):325–33.PubMedCrossRef
21.
Zurück zum Zitat Malvezzi M, Bosetti C, Rosso T, Bertuccio P, Chatenoud L, Levi F, et al. Lung cancer mortality in European men: trends and predictions. Lung Cancer. 2013;80(2):138–45.PubMedCrossRef Malvezzi M, Bosetti C, Rosso T, Bertuccio P, Chatenoud L, Levi F, et al. Lung cancer mortality in European men: trends and predictions. Lung Cancer. 2013;80(2):138–45.PubMedCrossRef
22.
Zurück zum Zitat Borras JM, Pinol JL, Izquierdo A, Borras J. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: lung cancer. Med Clin (Barc). 2008;131(Suppl 1):53–7.PubMedCrossRef Borras JM, Pinol JL, Izquierdo A, Borras J. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: lung cancer. Med Clin (Barc). 2008;131(Suppl 1):53–7.PubMedCrossRef
23.
Zurück zum Zitat Schiaffino A, Fernandez E, Kunst A, Borrell C, Garcia M, Borras JM, et al. Time trends and educational differences in the incidence of quitting smoking in Spain (1965–2000). Prev Med. 2007;45(2–3):226–32.PubMedCrossRef Schiaffino A, Fernandez E, Kunst A, Borrell C, Garcia M, Borras JM, et al. Time trends and educational differences in the incidence of quitting smoking in Spain (1965–2000). Prev Med. 2007;45(2–3):226–32.PubMedCrossRef
24.
Zurück zum Zitat Lopez MJ, Fernandez E, Perez-Rios M, Martinez-Sanchez JM, Schiaffino A, Galan I, et al. Impact of the 2011 Spanish smoking ban in hospitality venues: indoor secondhand smoke exposure and influence of outdoor smoking. Nicotine Tob Res. 2013;15(5):992–6.PubMedCrossRef Lopez MJ, Fernandez E, Perez-Rios M, Martinez-Sanchez JM, Schiaffino A, Galan I, et al. Impact of the 2011 Spanish smoking ban in hospitality venues: indoor secondhand smoke exposure and influence of outdoor smoking. Nicotine Tob Res. 2013;15(5):992–6.PubMedCrossRef
25.
26.
Zurück zum Zitat Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.PubMed Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.PubMed
27.
Zurück zum Zitat Marcos-Gragera R, Pollan M, Chirlaque MD, Guma J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3:iii):90–6. Marcos-Gragera R, Pollan M, Chirlaque MD, Guma J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3:iii):90–6.
28.
Zurück zum Zitat Clèries R, Martínez JM, Escribà JM, Esteban L, Pareja L, Borràs JM, et al. Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–2019 through a Bayesian approach. Cancer Epidemiology. 2010;34(3):244–56.PubMedCrossRef Clèries R, Martínez JM, Escribà JM, Esteban L, Pareja L, Borràs JM, et al. Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–2019 through a Bayesian approach. Cancer Epidemiology. 2010;34(3):244–56.PubMedCrossRef
29.
Zurück zum Zitat Ribes J, Pareja L, Esteban L, Cleries R. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: liver cancer. Med Clin (Barc). 2008;131(Suppl 1):83–7.PubMedCrossRef Ribes J, Pareja L, Esteban L, Cleries R. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: liver cancer. Med Clin (Barc). 2008;131(Suppl 1):83–7.PubMedCrossRef
30.
Zurück zum Zitat Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.PubMedCrossRef Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.PubMedCrossRef
Metadaten
Titel
Time trends of cancer incidence and mortality in Catalonia during 1993–2007
verfasst von
R. Clèries
L. Esteban
J. Borràs
R. Marcos-Gragera
A. Freitas
M. Carulla
M. Buxó
A. Puigdefàbregas
Á. Izquierdo
R. Gispert
J. Galceran
J. Ribes
Publikationsdatum
01.01.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 1/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1060-y

Weitere Artikel der Ausgabe 1/2014

Clinical and Translational Oncology 1/2014 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.